Momentum is picking up for diabetes-focused biotech MannKind (MNKD). Shares surged 36% this week after MannKind’s presentation at the American Diabetes Association’s conference …
It has been a rough five years for investors of diabetes-focused biotech MannKind (MNKD). Over the period, shares of the company have declined …
Buckle up, we’re in for a bumpy ride. The number of new coronavirus (COVID-19) cases continues to surge, and as such, the market’s …
If you’re on a budget, yet in a risk-tolerant mood, it’s worth taking a look at penny stocks – companies whose shares sell …
Despite MannKind (MNKD) reporting third-quarter revenue for diabetes drug Afrezza below H.C.
Yesterday, United Therapeutics (UTHR), MannKind’s (MNKD) partner for Technosphere treprostinil (TreT), hosted its Science Day 2018. MannKind’s dry powder inhalable treprostinil formulation for …
This week, MannKind (MNKD) announced a global partnership with United Therapeutics (UTHR) to develop and commercialize Technosphere treprostinil (TreT) dry powder inhalation for …
H.C.